Species
Organizations
Categories
Canine
Feline
Equine
Clear All
0
Refine Search
Species
Canine
Feline
Equine
Organizations
University of Guelph
ACI
Anivive Lifesciences
Midwestern University
University of Florida
Cornell
Categories
Endocrine/Metabolic
Infectious
Cardiovascular
Ophthalmic
Oncology
Internal Medicine
Clear All
All Studies (9)
Showing 1-9 of 9 Trials
University of Florida
University of Florida
•Canine
•Endocrine/Metabolic
•Observational
•1 Location
Canine Diabetes
University of Florida
•Canine
•Endocrine/Metabolic
•Observational
•1 Location

Diabetes mellitus is an important health problem in both dogs and people. Type 1 diabetes (T1D) in people is caused by an attack of the body’s own immune system on cells in the pancreas. Diabetes in dogs is thought to be similar in some ways to T1D in people, but there is still much more to learn about the causes of diabetes in dogs as well as better ways to prevent and treat the disease. The purpose of this study is to learn more about metabolism and immune function in diabetic dogs.

Read More
Canine Diabetes
Eligibility Criteria

Your dog has been recently diagnosed with canine diabetes

  • A diagnosis of Canine Diabetes within the last 4 weeks
  • Adult age (Older than 1 year)
  • Body weight greater than 6.5 lbs (3 kg)

Your dog has other endocrine related disease or is a non-spayed female

  • Non-spayed females
  • Current diagnosis of destrus diabetes or hyperadrenocorticism(Cushing's Disease)
  • Weight under 6.5 pounds
University of Florida
University of Florida
•Canine
•Cardiovascular
•Interventional
•1 Location
DCM in Dobermans
University of Florida
•Canine
•Cardiovascular
•Interventional
•1 Location

Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.

Read More
DCM in Dobermans
Eligibility Criteria

Your dog has been diagnosed with dilated cardiomyopathy

  • A diagnosis of DCM and previous evidence of congestive heart failure which has been controlled with medical management.
  • A circulating neutralizing antibody titer to the virus vector of less than 1:20
  • Owner agreement to authorize participation with informed consent and collection of the heart following euthanasia or death from any cause.

Your dog has no other heart conditions

  • Clear of extra-cardiac disease, congenital heart disease or primary mitral valvular disease
Anivive Lifesciences
Anivive Lifesciences
•Canine
•Oncology
•Interventional
•12 Locations
Canine Lymphoma
Anivive Lifesciences
•Canine
•Oncology
•Interventional
•12 Locations

Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.

Read More
Canine Lymphoma
Eligibility Criteria

Your dog has naïve or first relapse lymphoma

  • Naïve: dog who has not received any treatment for lymphoma.

  • First relapse: dog has failed a single round of any chemotherapy completed at least 14-days prior to study entry and has recovered from any acute toxicity from prior chemotherapy or is on prednisone and has exhibited progressive disease.

Your dog is over 1 year old and weighs more than 9kgs (~20lbs)

Your dog is ≥ 1 year, weighs ≥ 9 kg and has a life expectancy of at least 28 days.

Your dog has a diagnosis of lymphoma

Your dog has a diagnosis of lymphoma by cytology (fine needle aspirate of the lymph node) and/or histopathology (biopsy)

Cornell
Cornell
•Canine
•Oncology
•Interventional
•1 Location
Investigating a New Treatment for Hemangiosarcoma
Cornell
•Canine
•Oncology
•Interventional
•1 Location

Hemangiosarcoma is the most common splenic cancer diagnosed in dogs. The standard of care treatment is splenectomy (surgery) followed by doxorubicin chemotherapy, but long-term survival remains poor. We are continuously looking for additional well-tolerated treatments that may prolong survival for dogs with this disease.

Read More
Investigating a New Treatment for Hemangiosarcoma
Eligibility Criteria

Your dog has had a splenic Hemangiosarcoma

Your dog must have a splenic hemangiosarcoma that has been surgically removed either at a local veterinarian or at the CUHA. The diagnosis must have been confirmed with histopathology.

Exclusionary criteria

Your dog must not be on any supplements such as Yunnan baiyao or I'm Yunity/turkey tail mushroom.

Your dog must not have evidence of metastasis (spread of disease).

Cornell
Cornell
•Feline
•Interventional
•1 Location
Dietary Trial for Cats with IBD or GI Lymphoma
Cornell
•Feline
•Interventional
•1 Location

The clinical signs in some cats with chronic enteropathy (chronic vomiting and/or diarrhea) can be reversed with dietary management using a specially formulated diet. It is not clear why some cats respond to diet, or what the optimal composition of the diet for cats with chronic enteropathy should be. We want to know if diets containing proteins that are selected to minimize immune responses and fortified in Vitamin B12 and natural anti-inflammatory agents (prebiotics and curcumin) are better than conventional diets for cats with chronic enteropathy.

Read More
Dietary Trial for Cats with IBD or GI Lymphoma
Eligibility Criteria

Any Cat with signs of chronic GI disease

Your cat must have signs of chronic GI disease (of more than 3 weeks duration), have had non-GI causes of vomiting and/or diarrhea ruled out, and must be amenable to blood sampling at the times required by the study.

Your cat must currently be symptomatic.

Cornell
Cornell
•Canine
•Observational
•1 Location
Sequencing the Genes of Dogs with Acute Myeloid Leukemia
Cornell
•Canine
•Observational
•1 Location

Acute myeloid leukemia is a cancer of the blood. Although uncommon, it is a highly aggressive form of cancer and often kills dogs quickly, particularly because we don’t have many drugs that we can use to treat the leukemia. Great strides have been made in humans with acute myeloid leukemia, which is similar to the disease we see in dogs. However, unlike humans, we know very little about the genetic mutations that underlie acute myeloid leukemia in dogs, which is the goal of this study

Read More
Sequencing the Genes of Dogs with Acute Myeloid Leukemia
Eligibility Criteria

This is a sample-collection only study for dogs with acute leukemia

Dogs diagnosed with acute leukemia are eligible to participate.

Cornell
Cornell
•Canine
•Interventional
•1 Location
Selective Inhibition of Nuclear Export (SINE) and Canine Osteosarcoma
Cornell
•Canine
•Interventional
•1 Location

Osteosarcoma is a common cancer diagnosed in dogs, particularly in large breed dogs. While several chemotherapy protocols have been shown to provide modest management of the onset of metastasis (spread of cancer), we are continuously looking for additional treatments that may extend survival time. Carboplatin is a widely accepted chemotherapy agent used in treatment of osteosarcoma. The results of this study will allow us to determine if dogs can successfully tolerate carboplatin and a new drug called Laverdia-CA1 (verdinexor) in a combination protocol.

Read More
Selective Inhibition of Nuclear Export (SINE) and Canine Osteosarcoma
Eligibility Criteria

Your dog has been seen by CUHA

Patients must have been previously treated at Cornell University Hospital for Animals

Your dog has had limb amputation due to osteosarcoma

Patients must had been diagnosed with osteosarcoma and had limb amputation at Cornell University Hospital for Animals previously.

You dog has NOT received any chemotherapy

Patients must not have received chemotherapy treatment previously

Midwestern University
Midwestern University
•Canine
•Observational
•1 Location
Performance of a New Point-of-care Rapid Test to Diagnose Pulmonary Coccidioidomycosis
Midwestern University
•Canine
•Observational
•1 Location

Diagnosis of coccidioidomycosis in dogs is challenging due to the fact that the symptoms are not specific for this disease. Coccidioidomycosis can be diagnosed via a biopsy however the most common method is testing for antibodies to the fungus. These tests are often sent to third party labs delaying confirmation of the disease. This study looks to evaluate a potential point of care rapid test which would be able to provide a positive or negative result indicating the presence or absence of antibodies, respectively, within 30-60 minutes. The diagnosis of pulmonary coccidioidomycosis can be difficult because clinical signs overlap with many other respiratory tract disorders and dogs can have positive Valley Fever antibody titers without active clinical infection. Acute phase proteins are useful biomarkers for many other disorders and our hope is to determine whether they can facilitate making a diagnosis of pulmonary coccidioidomycosis in dogs. For additional details or questions please contact Dr. Jaffey (jjaffe@midwestern.edu).

Read More
Performance of a New Point-of-care Rapid Test to Diagnose Pulmonary Coccidioidomycosis
Eligibility Criteria

Your dog has a a confirmed or suspected novel diagnosis of pulmonary coccidioidomycosis

Your dog has a a confirmed or suspected novel diagnosis of pulmonary coccidioidomycosis

Your dog has at least 1 respiratory sign

Your dog has one of the following respiratory signs:

  • Cough

  • Exercise intolerance

  • Wheezing

  • Dyspnea

  • Tachypnea

  • Respiratory distress

Your dog has not received an anti-fungal treatment more than 7 days before enrollment

Dog must not have received an anti-fungal treatment for more than 7 days before enrollment

Midwestern University
Midwestern University
•Canine
•Interventional
•1 Location
Efficacy of twice-daily nebulized budesonide for the treatment of canine chronic bronchitis: a pilot study
Midwestern University
•Canine
•Interventional
•1 Location

Canine chronic bronchitis is an inflammatory disease characterized by a cough for > 2 months without another identifiable cause. Dogs with chronic bronchitis have persistent airway neutrophilic inflammation. The foundation of long-term therapy is corticosteroids. Oral prednisone is commonly used but has a litany of possible adverse effects. Inhaled steroids is an alternative to avoid the adverse effects of prednisone but the only available option is fluticasone. This medication is expensive and has variable efficacy. Inhaled budesonide is a medication used in humans to treat a similar airway disorder and is a fraction of the cost. This study aims to investigate the benefit of inhaled budesonide on respiratory tract symptoms in dogs with chronic bronchitis.

Read More
Efficacy of twice-daily nebulized budesonide for the treatment of canine chronic bronchitis: a pilot study
Eligibility Criteria

Your dog has a chronic cough for longer than 2 months

Dogs with a history of cough exceeding two months may be eligible for the study.

Your dog has thoracic radiographs performed in the past 3 months

Thoracic radiographs will be used by principal investigator to determine eligibility.

Your dog does NOT have an alternative cause for chronic cough

Dogs with alternative caused for chronic cough such as tracheal collapse, heart disease, cancer, Valley Fever, etc are not eligible for this study.

Your dog has not received previous treatment with corticosteroids

Dogs who have received previously received corticosteroids for treatment of chronic cough are not eligible for this study.

Recommended from Anivive
Canine Lymphoma
Canine Lymphoma
Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.
Investigating a New Treatment for Hemangiosarcoma
Investigating a New Treatment for Hemangiosarcoma
Hemangiosarcoma is the most common splenic cancer diagnosed in dogs. The standard of care treatment is splenectomy (surgery) followed by doxorubicin chemotherapy, but long-term survival remains poor. We are continuously looking for additional well-tolerated treatments that may prolong survival for dogs with this disease.
Performance of a New Point-of-care Rapid Test to Diagnose Pulmonary Coccidioidomycosis
Performance of a New Point-of-care Rapid Test to Diagnose Pulmonary Coccidioidomycosis
Diagnosis of coccidioidomycosis in dogs is challenging due to the fact that the symptoms are not specific for this disease. Coccidioidomycosis can be diagnosed via a biopsy however the most common method is testing for antibodies to the fungus. These tests are often sent to third party labs delaying confirmation of the disease. This study looks to evaluate a potential point of care rapid test which would be able to provide a positive or negative result indicating the presence or absence of antibodies, respectively, within 30-60 minutes. The diagnosis of pulmonary coccidioidomycosis can be difficult because clinical signs overlap with many other respiratory tract disorders and dogs can have positive Valley Fever antibody titers without active clinical infection. Acute phase proteins are useful biomarkers for many other disorders and our hope is to determine whether they can facilitate making a diagnosis of pulmonary coccidioidomycosis in dogs. For additional details or questions please contact Dr. Jaffey (jjaffe@midwestern.edu).
Anivive Trial Logo Black

CONTACT US

FacebookInstagramLinkedIn

Copyright © 2023 Anivive

All rights reserved | Terms of Use | Privacy Policy